Trial
NCT00815516
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Candidiasis
Intervention
micafungin
Why stopped
It was decided to discontinue the study due to insufficient recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-04